Aptamers in oncology: a diagnostic perspective

Nucleic acid sequences can produce a wide variety of three-dimensional conformations. Some of these structural forms are able to interact with proteins and small molecules with high affinity and specificity. These sequences, comprising either double or single stranded oligonucleotides, are called 'aptamers' based on the Greek word aptus, which means 'to fit'. Using an efficient selection process, randomised oligonucleotide libraries can be rapidly screened for aptamers with the appropriate binding characteristics. This technology has spawned the development of a new class of oligonucleotide therapeutic products. However, while interest among pharmaceutical companies continues to grow with some candidates already in clinical trials and one in the market, there appears to be some reluctance to fully explore the diagnostic potential of this technology. This article will review aptamer developments in diagnostics, compare them with other oligonucleotide therapeutics and highlight both potentials and pitfalls of technological development in this area

Design Strategies for Aptamer-Based Biosensors

Aptamers have been widely used as recognition elements for biosensor construction, especially in the detection of proteins or small molecule targets, and regarded as promising alternatives for antibodies in bioassay areas. In this review, we present an overview of reported design strategies for the fabrication of biosensors and classify them into four basic modes: target-induced structure switching mode, sandwich or sandwich-like mode, target-induced dissociation/displacement mode and competitive replacement mode. In view of the unprecedented advantages brought about by aptamers and smart design strategies, aptamer-based biosensors are expected to be one of the most promising devices in bioassay related applications

Aptamer-Functionalized Nano-Biosensors

Nanomaterials have become one of the most interesting sensing materials because of their unique size- and shape-dependent optical properties, high surface energy and surface-to-volume ratio, and tunable surface properties. Aptamers are oligonucleotides that can bind their target ligands with high affinity. The use of nanomaterials that are bioconjugated with aptamers for selective and sensitive detection of analytes such as small molecules, metal ions, proteins, and cells has been demonstrated. This review focuses on recent progress in the development of biosensors by integrating functional aptamers with different types of nanomaterials, including quantum dots, magnetic nanoparticles (NPs), metallic NPs, and carbon nanotubes. Colorimetry, fluorescence, electrochemistry, surface plasmon resonance, surface-enhanced Raman scattering, and magnetic resonance imaging are common detection modes for a broad range of analytes with high sensitivity and selectivity when using aptamer bioconjugated nanomaterials (Apt-NMs). We highlight the important roles that the size and concentration of nanomaterials, the secondary structure and density of aptamers, and the multivalent interactions play in determining the specificity and sensitivity of the nanosensors towards analytes. Advantages and disadvantages of the Apt-NMs for bioapplications are focused

Nanoparticle-Based Bioanalysis

Using electrical impedance spectroscopy, three nanoparticle-based detection schemes were investigated. In particular, reproducibility and ease of amplification were thoroughly analyzed. Though all three configurations successfully detected the presence of the target molecule (human IgE), the sensor utilizing an aptamer sandwich mechanism generated reproducible, large impedance changes in the presence of human IgE

Design of specific nucleic acid‐based biosensors for protein binding activity

Nucleic acid-based biosensors for the detection of specific proteins combine the typical programmability of synthetic DNA systems with artificially controlled DNA-protein communication. The high-affinity interaction between a target protein and a specific ligand, such as an aptamer sequence, or a double stranded DNA domain, or a small peptide, is paired with a nature-mimicking molecular mechanism allowing for probing, processing, and translating protein binding activity into a measurable signal. In this Review, two main strategies developed in the context of protein-responsive nucleic acid-based biosensors are discussed. One is the design of proximity-based assays harnessing the spatial colocalization of functional probes within the volume of a multivalent protein. The other is the engineering of dynamic DNA structures that undergo a controlled conformational or structural change upon protein binding. Examples of applications from optical and electrochemical detection of antibodies in biofluids to fluorescence imaging of transcription factors in living cells are reported, and suggestions along with possible future directions in the field are discussed

Mapping the gaps in chemical analysis for the characterisation of aptamer-target interactions

Aptamers are promising biorecognition elements with a wide applicability from therapeutics to biosensing. However, to successfully use these biomolecules, a complete characterisation of their binding performance in the presence of the target is crucial. Several multi-analytical approaches have been reported including techniques to describe kinetic and thermodynamic aspects of the aptamer-target interaction, and techniques which allow an in-depth understanding of the aptamer-target structures. Recent literature shows the need of a critical data interpretation, a combination of characterisation techniques and suggests the key role of the characterisation protocol design. Indeed, the final application of the aptamer should be considered before choosing the characterisation method. All the limitations and capabilities of the analytical tools in use for aptamer characterisation should be taken into account. Here, we present a critical overview of the current methods and multi-analytical approaches to study aptamer-target binding, aiming to provide researchers with guidelines for the design of characterisation protocols

Aptamer-based biosensors for biomedical diagnostics

Aptamers are single-stranded nucleic acids that selectively bind to target molecules. Most aptamers are obtained through a combinatorial biology technique called SELEX. Since aptamers can be isolated to bind to almost any molecule of choice, can be readily modified at arbitrary positions and they possess predictable secondary structures, this platform technology shows great promise in biosensor development. Over the past two decades, more than one thousand papers have been published on aptamer-based biosensors. Given this progress, the application of aptamer technology in biomedical diagnosis is still in a quite preliminary stage. Most previous work involves only a few model aptamers to demonstrate the sensing concept with limited biomedical impact. This Critical Review aims to summarize progress that might enable practical applications of aptamers for biological samples. First, general sensing strategies based on the unique properties of aptamers are summarized. Each strategy can be coupled to various signaling methods. Among these, a few detection methods including fluorescence lifetime, flow cytometry, upconverting nanoparticles, nanoflare technology, magnetic resonance imaging, electronic aptamer-based sensors, and lateral flow devices have been discussed in more detail since they are more likely to work in a complex sample matrix. The current limitations of this field include the lack of high quality aptamers for clinically important targets. In addition, the aptamer technology has to be extensively tested in a clinical sample matrix to establish reliability and accuracy. Future directions are also speculated to overcome these challenges.University of Waterloo || Natural Sciences and Engineering Research Council || Foundation for Shenghua Scholar of Central South University |

Universal fieldable assay with unassisted visual detection

A universal detection system based on allosteric aptamers, signal amplification cascade, and eye-detectable phrase transition. A broadly applicable homogeneous detection system is provided. It utilizes components of the blood coagulation cascade in the presence of polystyrene microspheres (MS) as a signal amplifier. Russell's viper venom factor X activator (RVV-X) triggers the cascade, which results in an eye-visible phase transition--precipitation of MS bound to clotted fibrin. An allosteric RNA aptamer, RNA132, with affinity for RVV-X and human vascular endothelial growth factor (VEGF.sub.165) was created. RNA132 inhibits enzymatic activity of RVV-X. The effector molecule, VEGF.sub.165, reverses the inhibitory activity of RNA132 on RVV-X and restores its enzymatic activity, thus triggering the cascade and enabling the phase transition. Similar results were obtained for another allosteric aptamer modulated by a protein tyrosine phosphatase. The assay is instrumentation-free for both processing and readout

Novel electrochemical aptamer-based sensing mechanism inspired by selection strategies

Des millions de patients souffrant d’insuffisance cardiaque bénéficieraient d’analyses sanguines hebdomadaires pour surveiller l’évolution de leur état de santé comme c’est le cas avec les personnes atteintes du diabète. Cependant, il n’existe pas de technologies d’analyses sanguines rapides et efficaces pour détecter des marqueurs d’insuffisance cardiaque, telle que la créatinine, la NT-proBNP et la troponine I par exemple. La possibilité pour les patients de surveiller leurs taux de créatinine régulièrement, du confort de chez soi, améliorerait largement leur qualité de vie ainsi que leur taux de survie. En suivant leur taux de créatinine, le patient pourrait prédire des signes d’insuffisance cardiaque, et ainsi faire ajuster leur plan de traitement en conséquence. Pour y arriver, les biocapteurs électrochimiques, dont un exemple est le glucomètre, représentent une classe prometteuse de dispositifs d’analyse sanguine puisqu’ils sont faciles à utiliser, rapides, peu coûteux, sensibles, stables et potentiellement universels. Les biocapteurs électrochimiques à base d’ADN pourraient potentiellement être adaptés en biocapteur de créatinine, par l’entremise d’aptamères. Le but de cette recherche est de développer un nouveau mécanisme de détection universel et efficace pouvant être adapté directement à partir des stratégies de sélection des aptamères. Pour ce faire, nous avons identifié et caractérisé un élément de bioreconnaissance sélectif pour la créatinine. Ensuite, nous avons conçu une nouvelle stratégie de détection et nous avons validé cette nouvelle stratégie par spectroscopie de fluorescence avant de l’adapter pour une détection électrochimique. Par la suite, nous avons optimisé les performances du biocapteur en modulant des paramètres analytiques tels que sa gamme linéaire et son gain de signal, tout en validant ses performances dans une matrice complexe comme le sérum. Les résultats de cette recherche suggèrent que la stratégie de conception du nouveau biocapteur électrochimique à base d’aptamère est prometteuse pour la détection efficace de biomarqueurs sanguins. Ce type de mécanisme pourrait être facilement adapté pour détecter d'autres molécules cliniquement pertinentes en modifiant simplement la stratégie de sélection de l'aptamère.Millions of patients suffering from heart failure would greatly benefit from weekly blood analysis to help them manage their disease state like patients suffering from diabetes. However, no simple blood monitoring technologies detecting heart failure biomarkers, such as creatinine, NT-proBNP, and troponin I, are available. The ability to determine and regularly monitor the creatinine level in the home setting would greatly improve the patient’s quality of life and survival rate. Knowing the concentration of creatinine help to predict heart failure and to revise the treatment plan if the concentration of creatinine is abnormal. To achieve this, electrochemical sensors, like a glucometer, represent a promising class of blood analysis devices due to their ease of use, fast response, low cost, inherent sensitivity and stability, and potential universality. More specifically, DNA-based electrochemical biosensors could potentially be adapted into a creatinine sensor by using aptamers specific to a biomarker. To achieve this goal, we identified a selective biorecognition element for creatinine detection and characterized it. We also designed a novel sensing aptamer-based strategy and validated this strategy by fluorescent spectroscopy before transposing it into the electrochemical format. We then optimized the performance of the sensor by tuning its signal gain and characterizing the dynamic range while also validating its performance in serum. The results of this work suggest that the electrochemical aptamer-based strategy represents a promising sensing mechanism. We believe this mechanism could be easily adapted to detect other clinically relevant molecules by simply relying on the aptamer’s selection strategy